# Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

> **NCT05286060** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yonsei University** · enrollment: 56 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** GX-188E, GX-I7, Pembrolizumab
- **DRUG:** GX-188E, Pembrolizumab
- **DRUG:** GX-188E, GX-I7, Pembrolizumab
- **DRUG:** GX-188E, GX-I7

## Key facts

- **NCT ID:** NCT05286060
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286060, "Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05286060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*